Appendix B: Panel Roster and Financial Disclosures
Invasive Mycoses
| Member | Institution | Financial Disclosure | |
|---|---|---|---|
| Company | Relationship | ||
| Neil Ampel | University of Arizona, College of Medicine | None | N/A |
| David Boulware | University of Minnesota Medical School |
Appili Therapeutics Matinas BioPharma |
Research Support (paid to institution) |
| Richard Hamill | Baylor College of Medicine | None | N/A |
| Carol Kauffman* | University of Michigan Medical School and Veterans Affairs Ann Arbor Healthcare System |
Cidara Laboratoires SMB S.A. |
Data Safety Monitoring Board |
| Marisa Miceli | University of Michigan Medical School |
SCYNEXIS F2G Mayne |
Research Support (paid to institution) |
| SCYNEXIS | Data Safety Monitoring Board | ||
| Astellas | Consulting | ||
| Peter Pappas | The University of Alabama at Birmingham, School of Medicine |
Astellas Pharma Merck |
Research Support (paid to institution) |
| Cidara Therapeutics | Scientific Advisory Board | ||
| SCYNEXIS | Advisory Board (Research Support) | ||
| John Perfect | Duke University, School of Medicine | Pfizer | Scientific Advisory Board |
| * Group lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. |
|||
Download Guidelines
- Section OnlyPDF (156.41 KB)
- Full GuidelinePDF (5.47 MB)
- Tables OnlyPDF (1.01 MB)